2-DG Concentration and Duration for Glycolysis Inhibition
Mechanism, and Where It Leaks
2-DG is transported by glucose transporters, phosphorylated by hexokinase, and not further metabolised, so it accumulates as 2-DG-6-phosphate and competitively inhibits glucose phosphorylation.
| Effect | Mechanism | Relevance |
|---|---|---|
| Glycolytic inhibition | Competition at hexokinase; G6P depletion | The intended effect |
| Glycosylation inhibition | 2-DG-6-phosphate competes in the hexosamine pathway | Induces ER stress and UPR at effective doses |
| G6P depletion | Loss of the PPP substrate | Reduces NADPH and nucleotide synthesis |
| Growth arrest | Loss of biosynthetic precursors | Confounds viability interpretation |
| Insulin-independent uptake modulation | Transporter regulation | Cell-type dependent |
Important distinction. The intracellular 2-DG-6-phosphate concentration, not the medium concentration, determines the effect, and it depends on transporter expression and on the glucose concentration in the medium. A 10 mM dose in low glucose is not the same experiment as 10 mM in high glucose.
Part 1 — Concentration Ranges
| Concentration | Typical context | Expected effect | Caveat |
|---|---|---|---|
| 1–5 mM | Sensitisation; tracer-adjacent use | Partial inhibition | Small effect; hard to resolve |
| 10–25 mM | Standard glycolysis blockade | Substantial inhibition within 30–60 min | Glycosylation effects begin |
| 50 mM | Seahorse injection; strong blockade | Near-complete inhibition | ER stress within the assay window |
| >50 mM | Rarely justified | Saturation of the transporter | Osmotic and toxicity effects |
The third row is the standard for a plate-based inhibition step, and it is at the upper end of what a mechanism claim should use. For a 24-hour treatment intended to test dependence, 10–25 mM with a viability control is usually more interpretable than 50 mM.
Part 2 — Duration and Kinetics
| Window | What happens | Design note |
|---|---|---|
| 5–15 min | G6P falls; glycolytic flux falls | Suitable for acute flux measurements |
| 30–60 min | Maximal biochemical effect; lactate release falls | Suitable for Seahorse and short flux assays |
| 2–6 h | Growth arrest begins; ATP may fall if OXPHOS is limited | Viability must be measured |
| 24 h | Cell-cycle arrest; UPR; possible apoptosis | The effect is no longer glycolysis-specific |
Readout note. At 24 hours, a 2-DG effect on a phenotype is compatible with glycolytic inhibition, with glycosylation inhibition, with ER stress, or with growth arrest. Isolating glycolysis requires a shorter window, or a rescue that restores the specific missing product.
Part 3 — Controls That Make the Claim Specific
| Control | What it tests | Interpretation |
|---|---|---|
| Mannose supplementation | Glycosylation versus glycolysis | Mannose restores glycosylation without restoring glycolysis; rescue by mannose indicates a glycosylation mechanism |
| Glucose titration | Competitive reversal | Reversal by excess glucose confirms hexokinase competition |
| Pyruvate or uridine supplementation | Downstream product replacement | Distinguishes ATP from biosynthetic precursor limitation |
| Viability and proliferation | Whether the phenotype is death | Essential at any dose above 10 mM |
| Osmolarity control | Non-specific osmotic effect | Matched osmolarity with an inert solute |
The first control is the most informative and the least used. Mannose enters the hexosamine pathway without feeding glycolysis, so a phenotype reversed by mannose is more likely a glycosylation effect than a bioenergetic one.
Part 4 — Using 2-DG as a Seahorse Injection
In the glycolysis stress test, 2-DG is injected last to establish the non-glycolytic acidification baseline.
- • Concentration: 50 mM final is conventional.
- • Timing: allow two to three measurement cycles after injection for the effect to complete.
- • Interpretation: the residual acidification is not zero, and includes respiratory and other contributions.
- • Caveat: at this dose and over this window, ER stress may begin, so the residual rate is a lower bound rather than a true non-glycolytic baseline.
Part 5 — Common Failures
- • Single high dose and a 24-hour endpoint, where the mechanism cannot be attributed.
- • Glucose concentration unrecorded, although it determines the effective inhibition.
- • No viability measurement, so growth arrest is reported as a metabolic effect.
- • Mannose control omitted in a long treatment.
- • 2-DG described as a glycolysis-specific inhibitor without qualification.
- • Osmolarity unmatched at 50 mM, where the solute load is substantial.
- • Injection artefact interpreted as a rate change in plate assays.
Part 6 — Where This Article Connects
This is the inhibitor counterpart to the pillar's dependence level: 2-DG is the fastest way to test whether a phenotype requires glycolysis, and the fastest way to produce an uninterpretable result if the window is too long. The Seahorse protocol article covers its use as an injection; the lactate article covers the alternative of measuring the product instead of inhibiting the pathway.
If you need glycolysis-dependence testing with mannose and pyruvate rescue controls, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Effective concentrations and the balance between glycolytic and glycosylation effects vary by cell type, transporter expression and medium glucose; the ranges here are starting points.
Inhibition of a pathway does not establish that the pathway is required for a phenotype unless the window and the rescue controls exclude alternative mechanisms.
Scientific interpretation and experimental design
- • Intracellular concentration drives the effect. Medium glucose matters.
- • Short windows are specific; long windows are not.
- • Mannose separates glycosylation from glycolysis.
- • Glucose titration confirms competition.
- • Measure viability above 10 mM.
- • 50 mM is a solute load. Match osmolarity.
Selected references for further reading
- • Wick AN, Drury DR, Nakada HI, Wolfe JB. Localization of the primary metabolic block produced by 2-deoxyglucose. Journal of Biological Chemistry. 1957;224:963–969.
- • Kurtoglu M, et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Molecular Cancer Therapeutics. 2007;6:3049–3058.
- • TeSlaa T, Teitell MA. Techniques to monitor glycolysis. Methods in Enzymology. 2014;542:91–114.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »